olodanrigan

Olodanrigan (formerly known as EMA401) is an orally bioavailable, highly selective small molecule antagonist of the angiotensin II type 2 receptor (AT2R). Originally developed by Spinifex Pharmaceuticals and subsequently acquired by Novartis, the compound was designed to treat chronic neuropathic pain by targeting peripheral mechanisms rather than the central nervous system. By antagonizing AT2R on peripheral sensory neurons, olodanrigan aims to inhibit the signaling pathways that lead to nociceptor sensitization and chronic pain states. It reached Phase 2 clinical trials for indications such as postherpetic neuralgia and painful diabetic neuropathy. However, in 2019, Novartis terminated the global clinical development program for olodanrigan after data from long-term preclinical toxicity studies indicated a potential risk of hepatotoxicity, which outweighed the benefit-risk profile for the intended patient populations.

Other names

olodanrigan